Gilead Sciences, Inc. (NASDAQ:GILD) will report Q2 2026 results Aug. 4 with a 4:30 PM ET webcast as data show its ISL/LEN weekly and PURPOSE twice‑yearly lenacapavir regimens sustain viral suppression and adherence, while EMA backs Trodelvy+Keytruda for PD‑L1+ TNBC, EU decision due 2026.
Previous Week Recap
- GILD To Report Q2 2026: Gilead (GILD) will report Q2 2026 results and guidance after market close Aug 4, 2026, with a 4:30 PM ET webcast. Live stream accessible to investors and archived for one year.
- GILD ISL/LEN Maintains Viral Suppression: Gilead’s ISL/LEN once-weekly regimen maintained viral suppression at Week 48 in ISLEND-1/2: 0–0.3% vs 0.3–1.3% on daily regimens. Safety similar; treatment-related AEs 13–18%.
- EMA Panel Approves Trodelvy/Kaytruda Combo: EMA panel recommended approval of Gilead's Trodelvy plus Keytruda as first-line therapy for unresectable/metastatic PD-L1–positive (CPS≥10) triple‑negative breast cancer; EU decision due in 2026.
- GILD PURPOSE 1/2 Long-Term Adherence: Gilead: PURPOSE 1/2 long-term open‑label data show twice‑yearly lenacapavir injections kept high adherence. PURPOSE 1: zero new HIV cases; PURPOSE 2: one infection. >95% opted to continue/switch.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.